These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

359 related articles for article (PubMed ID: 22204744)

  • 1. Outcomes of Pseudomonas eradication therapy in patients with non-cystic fibrosis bronchiectasis.
    White L; Mirrani G; Grover M; Rollason J; Malin A; Suntharalingam J
    Respir Med; 2012 Mar; 106(3):356-60. PubMed ID: 22204744
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early aggressive eradication therapy for intermittent Pseudomonas aeruginosa airway colonization in cystic fibrosis patients: 15 years experience.
    Hansen CR; Pressler T; Høiby N
    J Cyst Fibros; 2008 Nov; 7(6):523-30. PubMed ID: 18693078
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Inhaled colistin in elderly patients with non-cystic fibrosis bronchiectasis and chronic Pseudomonas aeruginosa bronchial infection].
    Tabernero Huguet E; Gil Alaña P; Alkiza Basañez R; Hernández Gil A; Garros Garay J; Artola Igarza JL
    Rev Esp Geriatr Gerontol; 2015; 50(3):111-5. PubMed ID: 25724860
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Eradication of initial Pseudomonas aeruginosa colonization in patients with cystic fibrosis.
    Griese M; Müller I; Reinhardt D
    Eur J Med Res; 2002 Feb; 7(2):79-80. PubMed ID: 11891148
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antimicrobial therapy for pulmonary pathogenic colonisation and infection by Pseudomonas aeruginosa in cystic fibrosis patients.
    Cantón R; Cobos N; de Gracia J; Baquero F; Honorato J; Gartner S; Alvarez A; Salcedo A; Oliver A; García-Quetglas E;
    Clin Microbiol Infect; 2005 Sep; 11(9):690-703. PubMed ID: 16104983
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early antibiotic treatment for Pseudomonas aeruginosa eradication in patients with cystic fibrosis: a randomised multicentre study comparing two different protocols.
    Taccetti G; Bianchini E; Cariani L; Buzzetti R; Costantini D; Trevisan F; Zavataro L; Campana S;
    Thorax; 2012 Oct; 67(10):853-9. PubMed ID: 22379071
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regimens for eradicating early Pseudomonas aeruginosa infection in children do not promote antibiotic resistance in this organism.
    Ho SA; Lee TW; Denton M; Conway SP; Brownlee KG
    J Cyst Fibros; 2009 Jan; 8(1):43-6. PubMed ID: 18829398
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Addition of inhaled tobramycin to ciprofloxacin for acute exacerbations of Pseudomonas aeruginosa infection in adult bronchiectasis.
    Bilton D; Henig N; Morrissey B; Gotfried M
    Chest; 2006 Nov; 130(5):1503-10. PubMed ID: 17099030
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of two treatment regimens for eradication of Pseudomonas aeruginosa infection in children with cystic fibrosis.
    Proesmans M; Vermeulen F; Boulanger L; Verhaegen J; De Boeck K
    J Cyst Fibros; 2013 Jan; 12(1):29-34. PubMed ID: 22762867
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The success of the different eradication therapy regimens for Pseudomonas aeruginosa in cystic fibrosis.
    Emiralioglu N; Yalcin E; Meral A; Sener B; Dogru D; Ozcelik U; Kiper N
    J Clin Pharm Ther; 2016 Aug; 41(4):419-23. PubMed ID: 27311742
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acquisition and eradication of P. aeruginosa in young children with cystic fibrosis.
    Douglas TA; Brennan S; Gard S; Berry L; Gangell C; Stick SM; Clements BS; Sly PD
    Eur Respir J; 2009 Feb; 33(2):305-11. PubMed ID: 19010992
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Early antibiotic treatment for eradication of initial infection by Pseudomonas aeruginosa in patients with cystic fibrosis].
    Giugno H; Castaños C; Lubatti A; Pinheiro JL; Hernández C; González Pena H
    Arch Argent Pediatr; 2010 Apr; 108(2):141-7. PubMed ID: 20467710
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Nocardia farcinica infection in a patient with cystic fibrosis].
    Beucher J; Belleguic C; Brinchault G; Deneuville E; Donnio PY; Roussey M
    Rev Mal Respir; 2010; 27(1):76-9. PubMed ID: 20146956
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Non cystic fibrosis bronchiectasis: A longitudinal retrospective observational cohort study of Pseudomonas persistence and resistance.
    McDonnell MJ; Jary HR; Perry A; MacFarlane JG; Hester KL; Small T; Molyneux C; Perry JD; Walton KE; De Soyza A
    Respir Med; 2015 Jun; 109(6):716-26. PubMed ID: 25200914
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Microbiological changes observed over 48 weeks of treatment with inhaled liposomal ciprofloxacin in individuals with non-cystic fibrosis bronchiectasis and chronic Pseudomonas aeruginosa lung infection.
    VanDevanter DR; Gonda I; Dahms J; Cipolla D; Davis AM; Chalmers JD; Froehlich J
    Clin Microbiol Infect; 2019 Dec; 25(12):1532-1538. PubMed ID: 31035017
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differences in prevalence and treatment of Pseudomonas aeruginosa in cystic fibrosis centres in Denmark, Norway and Sweden.
    Knudsen PK; Olesen HV; Høiby N; Johannesson M; Karpati F; Laerum BN; Meyer P; Pressler T; Lindblad A;
    J Cyst Fibros; 2009 Mar; 8(2):135-42. PubMed ID: 19157995
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Economic effects of an eradication protocol for first appearance of Pseudomonas aeruginosa in cystic fibrosis patients: 1995 vs. 2009.
    Lillquist YP; Cho E; Davidson AG
    J Cyst Fibros; 2011 May; 10(3):175-80. PubMed ID: 21310671
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Eradication Therapy against Pseudomonas aeruginosa in Non-Cystic Fibrosis Bronchiectasis.
    Orriols R; Hernando R; Ferrer A; Terradas S; Montoro B
    Respiration; 2015; 90(4):299-305. PubMed ID: 26340658
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhaled liposomal ciprofloxacin in patients with non-cystic fibrosis bronchiectasis and chronic lung infection with Pseudomonas aeruginosa (ORBIT-3 and ORBIT-4): two phase 3, randomised controlled trials.
    Haworth CS; Bilton D; Chalmers JD; Davis AM; Froehlich J; Gonda I; Thompson B; Wanner A; O'Donnell AE
    Lancet Respir Med; 2019 Mar; 7(3):213-226. PubMed ID: 30658914
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical impact of reducing routine susceptibility testing in chronic Pseudomonas aeruginosa infections in cystic fibrosis.
    Etherington C; Hall M; Conway S; Peckham D; Denton M
    J Antimicrob Chemother; 2008 Feb; 61(2):425-7. PubMed ID: 18156280
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.